-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
*For medical professionals only
This product is suitable for patients with
lupus who still have high disease activity after conventional treatment, and is suitable for adult patients
with systemic lupus erythematosus (SLE) who still have high disease activity (such as: anti-ds-DNA antibody positive and low complement, SELENA-SLEDAI score ≥8) and positive autoantibody on the basis of conventional treatment.
This indication is conditionally approved
based on the results of a Phase II clinical trial in adult patients with systemic lupus erythematosus who received conventional care and still had high disease activity.
Full approval for this indication will depend on confirmatory randomized controlled trials demonstrating clinical benefit in this patient population [1].
The recommended dose of this product is 160mg/time, administered once
a week.
During the administration of this product, after the clinician fully evaluates the safety and tolerability of the patient's use of this product, it is decided whether the dose
needs to be reduced.
If the dose needs to be reduced, the dose can be reduced to 80 mg per dose [1].
Not for patients with co-severe active infection Tatanercept should not be used to treat patients
with concomitant severe active infection.
B cells play an important role in maintaining a normal immune response, and treatment with tatacercept may increase the risk of infection based on the mechanism of therapeutic action of
tatacept.
Patients with active infection or severe impaired immune response should not use tatacept
.
Patients with a history of recurrent or chronic infection, or an underlying condition that predisposes to serious infection, should be treated with caution with tatacept
.
Patients who develop severe infections after treatment with tatacept should immediately stop the drug and start appropriate treatment
.
Which patients are not recommended for Titanercept? What are the symptoms of a tatalecept overdose? How to deal with it?
Where to see more common rheumatology medicines? Open "Clinical Decision Assistant - Evidence-based Medicine"
to search for related disease names/drug names, one click directly! 👇
, Ltd.
, 80mg/Sinopharm S20210008; Last revision date: 2021/03/09 ▼▼▼Click to read the original article to download the App
For more rheumatology drugs, go to the "Clinical Decision Assistant App"!
This product is suitable for patients with
lupus who still have high disease activity after conventional treatment, and is suitable for adult patients
with systemic lupus erythematosus (SLE) who still have high disease activity (such as: anti-ds-DNA antibody positive and low complement, SELENA-SLEDAI score ≥8) and positive autoantibody on the basis of conventional treatment.
This indication is conditionally approved
based on the results of a Phase II clinical trial in adult patients with systemic lupus erythematosus who received conventional care and still had high disease activity.
Full approval for this indication will depend on confirmatory randomized controlled trials demonstrating clinical benefit in this patient population [1].
The recommended dose of this product is 160mg/time, administered once
a week.
During the administration of this product, after the clinician fully evaluates the safety and tolerability of the patient's use of this product, it is decided whether the dose
needs to be reduced.
If the dose needs to be reduced, the dose can be reduced to 80 mg per dose [1].
Not for patients with co-severe active infection Tatanercept should not be used to treat patients
with concomitant severe active infection.
B cells play an important role in maintaining a normal immune response, and treatment with tatacercept may increase the risk of infection based on the mechanism of therapeutic action of
tatacept.
Patients with active infection or severe impaired immune response should not use tatacept
.
Patients with a history of recurrent or chronic infection, or an underlying condition that predisposes to serious infection, should be treated with caution with tatacept
.
Patients who develop severe infections after treatment with tatacept should immediately stop the drug and start appropriate treatment
.
Which patients are not recommended for Titanercept? What are the symptoms of a tatalecept overdose? How to deal with it?
Where to see more common rheumatology medicines? Open "Clinical Decision Assistant - Evidence-based Medicine"
to search for related disease names/drug names, one click directly! 👇
Download the Decision Assistant App and check it anytime, anywhere~
References: [1] Drug information: Tatanercept for injection, Rongchang Biopharmaceutical (Yantai) Co., Ltd.
, 80mg/Sinopharm S20210008; Last revision date: 2021/03/09 ▼▼▼Click to read the original article to download the App
